A daily pill called daraxonrasib combined with chemotherapy stopped tumour growth in 90% of patients with advanced pancreatic cancer in early trials, with cancer becoming undetectable on scans in one in 12 patients. The trial of 61 patients with recently diagnosed advanced pancreatic cancer that had spread followed participants for an average of 18 months. Some patients did not see their cancer return during this period.

Daraxonrasib is a targeted inhibitor that shuts off RAS mutations found in most pancreatic cancers that drive tumour growth. It has already received US approval. Doctors stress the drug should not be seen as a cure and longer studies are needed to understand how long remission might last.

Dr Wungki Park of Memorial Sloan Kettering Cancer Center, involved in the trial, said results showed "not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival." Cancer Research UK called the results "the biggest leap forward in decades" for pancreatic cancer patients. The drug may also help patients with lung and ovarian cancers that carry similar mutations.